Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
PERCEPTIVE ADVISORS LLC
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$5.1B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
94
positionsALL retained default holdings for this (filer, period), including NULL-value ones
20
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
42
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
PRAXIS PRECISION MEDICINES I COM NEWposition key pos:11991 · issuer key iss:1748 | add | +$67.7M | +40,000 | $588M | $656M | 1,995,986 | 2,035,986 | |
CELCUITY INC COMposition key pos:11232 · issuer key iss:542 | trim | +$41.7M | −33,000 | $315M | $357M | 3,160,200 | 3,127,200 | |
ASCENDIS PHARMA A/S SPONSORED ADRposition key pos:16862 · issuer key iss:252 | add | +$120M | +450,000 | $231M | $350M | 1,081,421 | 1,531,421 | |
ROIVANT SCIENCES LTD SHSposition key pos:18572 · issuer key iss:2604 | add | +$56.2M | +300,000 | $173M | $230M | 7,985,461 | 8,285,461 | |
CENTESSA PHARMACEUTICALS PLC SPONSORED ADSposition key pos:18882 · issuer key cusip6:152309 | add | +$136M | +2,341,269 | $73.0M | $209M | 2,917,634 | 5,258,903 | |
RHYTHM PHARMACEUTICALS INC COMposition key pos:17607 · issuer key iss:1846 | trim | −$66.1M | −172,596 | $273M | $206M | 2,546,391 | 2,373,795 | |
SPYRE THERAPEUTICS INC COM NEWposition key pos:14500 · issuer key iss:82 | add | +$90.3M | +714,000 | $101M | $191M | 3,069,225 | 3,783,225 | |
NUVALENT INC COMposition key pos:14079 · issuer key iss:1594 | trim | −$5.6M | −84,600 | $167M | $162M | 1,665,105 | 1,580,505 | |
EDGEWISE THERAPEUTICS INC COMposition key pos:12663 · issuer key iss:796 | trim | +$28.7M | −34,000 | $111M | $139M | 4,457,974 | 4,423,974 | |
PROTAGONIST THERAPEUTICS INC COMposition key pos:14826 · issuer key iss:1773 | trim | +$11.8M | −119,546 | $118M | $130M | 1,350,425 | 1,230,879 | |
APOGEE THERAPEUTICS INC COMposition key pos:14112 · issuer key iss:217 | trim | −$46.3M | −790,267 | $176M | $130M | 2,330,651 | 1,540,384 | |
TRAVERE THERAPEUTICS INC COMposition key pos:18617 · issuer key iss:2158 | trim | −$40.4M | −135,629 | $163M | $123M | 4,278,180 | 4,142,551 | |
RELAY THERAPEUTICS INC COMposition key pos:13232 · issuer key iss:1829 | add | +$80.9M | +7,847,896 | $16.1M | $97.0M | 1,903,245 | 9,751,141 | |
INHIBRX BIOSCIENCES INC COMposition key pos:16847 · issuer key iss:1178 | trim | −$17.8M | −10,000 | $115M | $97.0M | 1,452,707 | 1,442,707 | |
ZYMEWORKS INC COMposition key sid:sec:prov:cc436d9af4067ff4382c62284d4ff9e5 · issuer key cusip6:98985Y | add | +$2.0M | +248,228 | $85.9M | $87.9M | 3,261,850 | 3,510,078 | |
SOLID BIOSCIENCES INC COM NEWposition key pos:12592 · issuer key iss:2004 | add | +$19.0M | +73,107 | $66.7M | $85.7M | 11,833,539 | 11,906,646 | |
DYNE THERAPEUTICS INC COMposition key pos:14578 · issuer key iss:778 | add | +$16.6M | +1,189,895 | $68.0M | $84.6M | 3,478,944 | 4,668,839 | |
BIOCRYST PHARMACEUTICALS INC COMposition key pos:15962 · issuer key iss:374 | add | +$46.1M | +4,271,504 | $24.7M | $70.8M | 3,162,529 | 7,434,033 | |
ORUKA THERAPEUTICS INC COMposition key pos:14688 · issuer key iss:1638 | trim | +$23.7M | −81,000 | $44.8M | $68.4M | 1,476,501 | 1,395,501 | |
ARTIVION INC COMposition key pos:18864 · issuer key iss:688 | trim | −$18.6M | −85,000 | $78.6M | $60.0M | 1,722,290 | 1,637,290 | |
NURIX THERAPEUTICS INC COMposition key sid:sec:prov:48ac0f50c981e01f7c5af17d58a117cf · issuer key cusip6:67080M | add | −$9.9M | +155,000 | $67.5M | $57.5M | 3,555,877 | 3,710,877 | |
MODERNA INC COMposition key pos:13354 · issuer key iss:1490 PUT | new | +$50.8M | +1,000,000 | $0 | $50.8M | — | 1,000,000 | |
CYTOMX THERAPEUTICS INC. COMposition key sid:sec:prov:16b2967c1b0bb76b6346bfde109e0bb6 · issuer key cusip6:23284F | add | +$6.2M | +418,639 | $41.2M | $47.5M | 9,680,185 | 10,098,824 | |
ALTO NEUROSCIENCE INC COM SHSposition key sid:sec:prov:d8f1dce881f876173d775baaae476159 · issuer key cusip6:02157Q | add | +$13.4M | +225,500 | $31.8M | $45.2M | 1,784,393 | 2,009,893 | |
ENGENE HOLDINGS INC COMposition key sid:sec:prov:c58e51841f60c26aab31f70d6e4eabc3 · issuer key cusip6:29286M | trim | −$13.3M | −41,570 | $53.0M | $39.7M | 5,869,076 | 5,827,506 | |
IMMUNOVANT INC COMposition key sid:sec:prov:c0680e314bfe2d1131f5c3d642c67920 · issuer key cusip6:45258J | trim | −$11.0M | −397,507 | $50.7M | $39.7M | 1,994,890 | 1,597,383 | |
INTUITIVE SURGICAL INC COM NEWposition key pos:17712 · issuer key iss:1213 | trim | −$10.4M | −2,500 | $49.8M | $39.4M | 87,919 | 85,419 | |
IONIS PHARMACEUTICALS INC COMposition key pos:12370 · issuer key iss:1221 | new | +$37.8M | +504,000 | $0 | $37.8M | — | 504,000 | |
DAY ONE BIOPHARMACEUTICALS I COMposition key sid:sec:prov:5fa73bae4b4007f19790df8489a7fcc7 · issuer key cusip6:23954D | new | +$37.6M | +1,755,799 | $0 | $37.6M | — | 1,755,799 | |
ABIVAX SA SPONSORED ADSposition key pos:13227 · issuer key iss:50 | trim | −$25.2M | −129,459 | $61.8M | $36.6M | 458,343 | 328,884 | |
CORVUS PHARMACEUTICALS INC COMposition key sid:sec:prov:990effbc09610fc927e1edc54d252d9d · issuer key cusip6:221015 | add | +$28.2M | +1,600,000 | $5.3M | $33.5M | 692,441 | 2,292,441 | |
REPLIGEN CORP COMposition key pos:13464 · issuer key iss:1834 | trim | −$18.7M | −35,000 | $51.7M | $33.1M | 315,541 | 280,541 | |
DAMORA THERAPEUTICS INC COM NEWposition key pos:17113 · issuer key iss:983 | new | +$31.7M | +1,223,000 | $0 | $31.7M | — | 1,223,000 | |
X4 PHARMACEUTICALS INC COM NEWposition key sid:sec:prov:19b9675407eb505d5af586b26c66f53a · issuer key cusip6:98420X | add | +$2.6M | +423,196 | $25.3M | $27.8M | 6,314,452 | 6,737,648 | |
GUARDANT HEALTH INC COMposition key pos:18541 · issuer key iss:1057 | add | +$11.4M | +140,000 | $16.3M | $27.7M | 160,000 | 300,000 | |
BRIGHT MINDS BIOSCIENCES INC COM NEWposition key sid:sec:prov:fed138ced9737b90542a54b9484d2da0 · issuer key cusip6:10919W | trim | −$7.5M | −71,746 | $35.1M | $27.5M | 449,290 | 377,544 | |
INVIVYD INC COMposition key sid:sec:prov:de0907d604dc0fc94b1a3f8dd009ab9f · issuer key cusip6:00534A | trim | −$26.7M | −925,863 | $53.8M | $27.1M | 21,785,166 | 20,859,303 | |
SIONNA THERAPEUTICS INC COMposition key pos:11054 · issuer key iss:1980 | trim | −$22.1M | −520,659 | $48.5M | $26.4M | 1,179,098 | 658,439 | |
AXSOME THERAPEUTICS INC. COMposition key pos:13938 · issuer key iss:295 | add | −$1.9M | +1,050 | $27.2M | $25.3M | 148,900 | 149,950 | |
REVOLUTION MEDICINES INC COMposition key pos:15541 · issuer key iss:1842 | new | +$25.1M | +258,600 | $0 | $25.1M | — | 258,600 | |
SAB BIOTHERAPEUTICS INC COM NEWposition key sid:sec:prov:03d750f8ea50214fdbd147c22363d0f6 · issuer key cusip6:78397T | add | +$21.6M | +5,628,533 | $3.0M | $24.6M | 803,210 | 6,431,743 | |
BELITE BIO INC SPONSORED ADSposition key sid:sec:prov:831c753eb8a6ce9972092ec4165601d4 · issuer key cusip6:07782B | trim | −$42.0M | −262,260 | $66.3M | $24.2M | 414,239 | 151,979 | |
TENAX THERAPEUTICS INC COM NEWposition key sid:sec:prov:9e958f4e10d0d474cc9e75d42ea33a9a · issuer key cusip6:88032L | add | +$17.8M | +1,008,640 | $5.4M | $23.2M | 439,142 | 1,447,782 | |
AXOGEN INC COMposition key sid:sec:prov:fd61a14f8c16900d70648b14bc187bfb · issuer key cusip6:05463X | trim | −$2.6M | −86,828 | $25.7M | $23.1M | 784,140 | 697,312 | |
VIRIDIAN THERAPEUTICS INC COMposition key sid:sec:prov:4b145c10f034612809a5ead021971789 · issuer key cusip6:92790C | trim | −$71.8M | −1,871,874 | $94.7M | $22.9M | 3,042,703 | 1,170,829 | |
ORCHESTRA BIOMED HLDGS INC COMposition key sid:sec:prov:9f123b52d9dfa5657af06135ef52f112 · issuer key cusip6:68572M | trim | +$133K | −89,350 | $21.3M | $21.4M | 5,127,256 | 5,037,906 | |
DBV TECHNOLOGIES S A SPONSORED ADSposition key sid:sec:prov:097fe4205cdb81b5acf642533490216f · issuer key cusip6:23306J | new | +$20.1M | +964,391 | $0 | $20.1M | — | 964,391 | |
ANTERIS TECHNOLOGIES GLOBAL COMposition key sid:sec:prov:0d957017a1f6113a5600ce99517cee7f · issuer key cusip6:03675P | add | +$10.7M | +1,750,000 | $8.4M | $19.0M | 1,675,476 | 3,425,476 | |
SUTRO BIOPHARMA INC COM SHSposition key sid:sec:prov:c4149a9e14976bb08df8d6a0cb6dd6b6 · issuer key cusip6:869367 | new | +$17.8M | +715,307 | $0 | $17.8M | — | 715,307 | |
TANGO THERAPEUTICS INC COMposition key pos:12388 · issuer key iss:2086 | add | +$12.4M | +295,118 | $4.5M | $16.9M | 513,035 | 808,153 | |
CONTINEUM THERAPEUTICS INC CL Aposition key sid:sec:prov:05537d56ca21ce3a27a9a933baf06b09 · issuer key cusip6:21217B | trim | −$342K | −209,000 | $16.7M | $16.4M | 1,464,592 | 1,255,592 | |
PALISADE BIO INC COMposition key sid:sec:prov:fefbed769ea5db09695bd4a0f3004463 · issuer key cusip6:696389 | trim | −$12.7M | −3,121,851 | $28.3M | $15.6M | 12,050,000 | 8,928,149 | |
IRHYTHM HOLDINGS INC COMposition key pos:13207 · issuer key iss:1153 | trim | −$6.8M | −2,974 | $19.2M | $12.4M | 108,000 | 105,026 | |
EVOMMUNE INC COM SHSposition key sid:sec:prov:adbff6ad799c41f5a1fe4cddc6ffc42b · issuer key cusip6:30054Y | new | +$10.3M | +448,350 | $0 | $10.3M | — | 448,350 | |
PHATHOM PHARMACEUTICALS INC COMposition key sid:sec:prov:7715098c333bbe982e541f4b97bf5506 · issuer key cusip6:71722W | new | +$10.3M | +925,000 | $0 | $10.3M | — | 925,000 | |
NEUMORA THERAPEUTICS INC. COMposition key sid:sec:prov:87e5cb91aeaa35f0c2f2443d9f9aa785 · issuer key cusip6:640979 | new | +$10.0M | +5,104,097 | $0 | $10.0M | — | 5,104,097 | |
OMADA HEALTH INC COMposition key sid:sec:prov:748c3ea2043f7dae881221f3c766e002 · issuer key cusip6:68170A | trim | −$27.9M | −1,610,000 | $37.8M | $9.9M | 2,396,330 | 786,330 | |
NEUROCRINE BIOSCIENCES INC COMposition key pos:12315 · issuer key iss:1552 | trim | −$38.4M | −266,000 | $47.0M | $8.6M | 331,050 | 65,050 | |
BETA BIONICS INC COMposition key sid:sec:prov:4e7eb09ab13c64fd6730ede8dbc988b8 · issuer key cusip6:08659B | add | −$9.9M | +240,000 | $18.4M | $8.4M | 602,944 | 842,944 | |
OPUS GENETICS INC COMposition key sid:sec:prov:bb257ab3c32f69680923bbff7b61bc99 · issuer key cusip6:67577R | trim | −$340K | −2,489,158 | $8.7M | $8.4M | 4,325,000 | 1,835,842 | |
BILLIONTOONE INC CL Aposition key pos:19129 · issuer key iss:371 | add | +$1.3M | +19,000 | $6.0M | $7.2M | 72,812 | 91,812 | |
TWIST BIOSCIENCE CORP COMposition key pos:18059 · issuer key iss:2177 | new | +$7.1M | +150,000 | $0 | $7.1M | — | 150,000 | |
SURROZEN INC COM NEWposition key sid:sec:prov:0d3c6673b7060f8873ebd8344c73bee8 · issuer key cusip6:86889P | new | +$6.7M | +229,393 | $0 | $6.7M | — | 229,393 | |
AGOMAB THERAPEUTICS NV SPONSORED ADSposition key sid:sec:prov:fb9ea7ee3bb27d4ceeeb748915397758 · issuer key cusip6:00860C | new | +$6.3M | +600,000 | $0 | $6.3M | — | 600,000 | |
EVOLUS INC COMposition key sid:sec:prov:3c1bdde45f78766466db92da273259f5 · issuer key cusip6:30052C | new | +$5.3M | +1,286,862 | $0 | $5.3M | — | 1,286,862 | |
OCULAR THERAPEUTIX INC COMposition key sid:sec:prov:26fd673c04b9acd4e799cbdab734d215 · issuer key cusip6:67576A CALL | new | +$4.2M | +500,000 | $0 | $4.2M | — | 500,000 | |
ADMA BIOLOGICS INC COMposition key pos:15764 · issuer key iss:10 | trim | −$11.9M | −416,235 | $16.1M | $4.2M | 883,468 | 467,233 | |
INHIBIKASE THERAPEUTICS INC COM NEWposition key sid:sec:prov:8cb65945c1d745d32abfa3ce25a4d2e9 · issuer key cusip6:45719W | trim | −$7.2M | −3,106,568 | $11.1M | $3.9M | 5,421,568 | 2,315,000 | |
CRESCENT BIOPHARMA INC. COMposition key pos:17611 · issuer key iss:2481 | trim | −$1.6M | −246,744 | $5.4M | $3.8M | 453,686 | 206,942 | |
APELLIS PHARMACEUTICALS INC COMposition key sid:sec:prov:233302be8852a126d4f3dc726082a4c4 · issuer key cusip6:03753U | new | +$3.3M | +80,956 | $0 | $3.3M | — | 80,956 | |
EDESA BIOTECH INC COM NEWposition key sid:sec:prov:626869004f126eefd6f21e4a4f5ae60f · issuer key cusip6:27966L | new | +$2.9M | +563,239 | $0 | $2.9M | — | 563,239 | |
ADAPTIVE BIOTECHNOLOGIES COR COMposition key pos:16214 · issuer key iss:67 | new | +$2.1M | +152,500 | $0 | $2.1M | — | 152,500 | |
CORCEPT THERAPEUTICS INC COMposition key pos:16992 · issuer key iss:652 | new | +$2.0M | +50,000 | $0 | $2.0M | — | 50,000 | |
PALATIN TECHNOLOGIES INC COM NEWposition key sid:sec:prov:72475b3732ae8a64b486fe41b469bb0b · issuer key cusip6:696077 | trim | +$2.5K | −8,055 | $1.1M | $1.1M | 70,000 | 61,945 | |
CUMBERLAND PHARMACEUTICALS I COMposition key sid:sec:prov:98b422204b4d90393e978b5ebac79307 · issuer key cusip6:230770 | trim | −$717K | −144,109 | $1.4M | $640K | 341,087 | 196,978 | |
EXAGEN INC COMposition key sid:sec:prov:6cea3d644720599797447228551acb50 · issuer key cusip6:30068X | new | +$345K | +114,893 | $0 | $345K | — | 114,893 | |
| pos:10981 PUT | exit‡e | −$134M | −1,100,000 | $134M | $0 | 1,100,000 | — | |
| pos:11227 | exit‡e | −$34.4M | −110,529 | $34.4M | $0 | 110,529 | — | |
| pos:12302 | exit‡e | −$21.8M | −124,000 | $21.8M | $0 | 124,000 | — | |
| pos:12357 | exit‡e | −$20.5M | −259,545 | $20.5M | $0 | 259,545 | — | |
| pos:13022 | exit‡e | −$35.8M | −450,743 | $35.8M | $0 | 450,743 | — | |
| pos:13247 | exit‡e | −$21.7M | −4,185,632 | $21.7M | $0 | 4,185,632 | — | |
| pos:13384 | exit‡e | −$9.0M | −200,791 | $9.0M | $0 | 200,791 | — | |
| pos:13465 | exit‡e | −$5.4M | −69,935 | $5.4M | $0 | 69,935 | — | |
| pos:13498 | exit‡e | −$20.3M | −237,342 | $20.3M | $0 | 237,342 | — | |
| pos:14228 | exit‡e | −$17.5M | −220,000 | $17.5M | $0 | 220,000 | — | |
| pos:14505 | exit‡e | −$3.6M | −202,400 | $3.6M | $0 | 202,400 | — | |
| pos:14561 CALL | exit‡e | −$5.6M | −500,000 | $5.6M | $0 | 500,000 | — | |
| pos:14811 | exit‡e | −$4.1M | −165,713 | $4.1M | $0 | 165,713 | — | |
| pos:14974 | exit‡e | −$93.3M | −979,000 | $93.3M | $0 | 979,000 | — | |
| pos:15092 | exit‡e | −$30.7M | −1,136,206 | $30.7M | $0 | 1,136,206 | — | |
| pos:15762 | exit‡e | −$5.4M | −829,870 | $5.4M | $0 | 829,870 | — | |
| pos:15920 | exit‡e | −$15.0M | −225,758 | $15.0M | $0 | 225,758 | — | |
| pos:16031 | exit‡e | −$45.8M | −200,000 | $45.8M | $0 | 200,000 | — | |
| pos:16702 | exit‡e | −$15.8M | −140,000 | $15.8M | $0 | 140,000 | — | |
| pos:17789 | exit‡e | −$4.3M | −17,500 | $4.3M | $0 | 17,500 | — | |
| sid:sec:prov:0983c227d7f489fadce1abda0a417532 | exit‡e | −$28.0M | −825,890 | $28.0M | $0 | 825,890 | — | |
| sid:sec:prov:2452fdde4d0b3fb9db6ac52c91059345 | exit‡e | −$739K | −108,694 | $739K | $0 | 108,694 | — | |
| sid:sec:prov:25db868bd92949401541405f5298734d | exit‡e | −$9.7M | −550,000 | $9.7M | $0 | 550,000 | — | |
| sid:sec:prov:287679ae59495e28d5c5c22eea9bb86e | exit‡e | −$4.8M | −747,193 | $4.8M | $0 | 747,193 | — |
80 more changes below.
1–100 of 118 changes
Mark-to-market only (no share change) · 18
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
AMYLYX PHARMACEUTICALS INC COMposition key sid:sec:prov:6456a8a739b1b376bb8de72f440b1279 · issuer key cusip6:03237H | no change | +$15.1M | 0 | $100M | $115M | 8,284,882 | 8,284,882 | |
IMMATICS N.V SHSposition key sid:sec:prov:8771e17f16590b5bd511978f2a4f7807 · issuer key cusip6:N44445 | no change | −$6.9M | 0 | $109M | $102M | 10,383,456 | 10,383,456 | |
MEIRAGTX HLDGS PLC COMposition key sid:sec:prov:8c4f97ba195668adc97a71db173c878f · issuer key cusip6:G59665 | no change | +$7.2M | 0 | $82.1M | $89.3M | 10,326,103 | 10,326,103 | |
NAUTILUS BIOTECHNOLOGY INC COMposition key sid:sec:prov:f31df07e345986c48938525dc4cc3840 · issuer key cusip6:63909J | no change | +$24.3M | 0 | $24.6M | $48.9M | 12,594,211 | 12,594,211 | |
JAZZ PHARMACEUTICALS PLC SHS USDposition key pos:15540 · issuer key iss:2545 | no change | +$3.2M | 0 | $28.9M | $32.1M | 170,000 | 170,000 | |
RAPPORT THERAPEUTICS INC COMposition key sid:sec:prov:9fd554b76cc510ac236cd887d1f06195 · issuer key cusip6:75383L | no change | +$640K | 0 | $20.4M | $21.1M | 673,923 | 673,923 | |
LEONABIO INC COMposition key sid:sec:prov:b4fb61062116268ce297ca59ebf42283 · issuer key cusip6:04746L | no change | +$5.0M | 0 | $14.1M | $19.1M | 1,859,322 | 1,859,322 | |
CELCUITY INC NOTE 2.750% 8/0position key pos:16258 · issuer key iss:542 PRN | no change | +$1.8M | 0 | $14.1M | $15.9M | 6,500,000 | 6,500,000 | |
OCULIS HOLDING AG ORDINARY SHARESposition key sid:sec:prov:d3e1798d38ce2deff0ab7c16a87c8200 · issuer key cusip6:H5870P | no change | +$3.3M | 0 | $9.9M | $13.1M | 493,827 | 493,827 | |
ADAGIO MED HLDGS INC COMposition key sid:sec:prov:6298dc09e56171c0480b6cc0aa78c0e3 · issuer key cusip6:00534B | no change | +$741K | 0 | $10.3M | $11.0M | 9,876,576 | 9,876,576 | |
COGENT BIOSCIENCES INC COMposition key pos:18333 · issuer key iss:610 | no change | +$360K | 0 | $4.3M | $4.7M | 121,082 | 121,082 | |
OUTSET MED INC COM NEWposition key sid:sec:prov:4dc05f0d17e502f7e6fe21a62e2414d3 · issuer key cusip6:690145 | no change | +$108K | 0 | $3.1M | $3.2M | 833,333 | 833,333 | |
AVALO THERAPEUTICS INC COM NEWposition key sid:sec:prov:37b91915f07af95197894a79df85a91e · issuer key cusip6:05338F | no change | −$451K | 0 | $2.5M | $2.1M | 139,667 | 139,667 | |
CONNECT BIOPHARMA HLDGS LTD SHSposition key sid:sec:prov:de9b2d81435d99f71f774196a3faaaf5 · issuer key cusip6:G23549 | no change | −$159K | 0 | $2.2M | $2.1M | 792,696 | 792,696 | |
MEDLINE INC COM CL Aposition key pos:16301 · issuer key iss:1457 | no change | +$70.0K | 0 | $1.2M | $1.2M | 28,000 | 28,000 | |
REVOLUTION MEDICINES INC *W EXP 12/17/202position key pos:14583 · issuer key iss:1842 | no change | +$213K | 0 | $235K | $448K | 250,000 | 250,000 | |
ENSYSCE BIOSCIENCES INC COM NEWposition key sid:sec:prov:ea6b923dce62f9f92bb1b29b6ae9b9d1 · issuer key cusip6:293602 | no change | −$33.1K | 0 | $79.7K | $46.7K | 86,666 | 86,666 | |
SURROZEN INC *W EXP 08/01/203position key sid:sec:prov:c4f97db1890f36f80c7a359d19822318 · issuer key cusip6:86889P | no change | −$666 | 0 | $3.3K | $2.7K | 166,666 | 166,666 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 77.2%below median 80.0%
- Concentration index
- 410 bpsbelow median 446 bps
- Positions with value
- 94 / 94median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 77.2% · HHI (bps) ·§: 410integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 136
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open PERCEPTIVE ADVISORS LLC's 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–91 of 91 issuers · $5.1B disclosed value over 94 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | PRAXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PRAXIS PRECISION MEDICINES I PRAXIS PRECISION MEDICINES I · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $656M | 2,035,986 | — | 12.8% | — | |
| — | CELCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CELCUITY INC | $373M | — | — | 7.3% | — | |
| — | ASNDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ASCENDIS PHARMA A/S ASCENDIS PHARMA A/S · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $350M | 1,531,421 | — | 6.8% | — | |
| — | ROIVverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ROIVANT SCIENCES LTD ROIVANT SCIENCES LTD · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $230M | 8,285,461 | — | 4.5% | — | |
| — | — | CENTESSA PHARMACEUTICALS PLC CENTESSA PHARMACEUTICALS PLC · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $209M | 5,258,903 | — | 4.1% | — | |
| — | RYTMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | RHYTHM PHARMACEUTICALS INC RHYTHM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $206M | 2,373,795 | — | 4.0% | — | |
| — | SYREverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SPYRE THERAPEUTICS INC SPYRE THERAPEUTICS INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $191M | 3,783,225 | — | 3.7% | — | |
| — | NUVLverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NUVALENT INC NUVALENT INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $162M | 1,580,505 | — | 3.2% | — | |
| — | EWTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | EDGEWISE THERAPEUTICS INC EDGEWISE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $139M | 4,423,974 | — | 2.7% | — | |
| — | PTGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PROTAGONIST THERAPEUTICS INC PROTAGONIST THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $130M | 1,230,879 | — | 2.5% | — | |
| — | APGEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | APOGEE THERAPEUTICS INC APOGEE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $130M | 1,540,384 | — | 2.5% | — | |
| — | TVTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TRAVERE THERAPEUTICS INC TRAVERE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $123M | 4,142,551 | — | 2.4% | — | |
| — | — | AMYLYX PHARMACEUTICALS INC AMYLYX PHARMACEUTICALS INC · COM CUSIP 03237H101 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $115M | 8,284,882 | — | 2.3% | — | |
| — | — | IMMATICS N.V IMMATICS N.V · SHS CUSIP N44445109 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $102M | 10,383,456 | — | 2.0% | — | |
| — | RLAYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | RELAY THERAPEUTICS INC RELAY THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $97.0M | 9,751,141 | — | 1.9% | — | |
| — | INBXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INHIBRX BIOSCIENCES INC INHIBRX BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $97.0M | 1,442,707 | — | 1.9% | — | |
| — | — | MEIRAGTX HLDGS PLC MEIRAGTX HLDGS PLC · COM CUSIP G59665102 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $89.3M | 10,326,103 | — | 1.7% | — | |
| — | — | ZYMEWORKS INC ZYMEWORKS INC · COM CUSIP 98985Y108 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $87.9M | 3,510,078 | — | 1.7% | — | |
| — | SLDBverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SOLID BIOSCIENCES INC SOLID BIOSCIENCES INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $85.7M | 11,906,646 | — | 1.7% | — | |
| — | DYNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DYNE THERAPEUTICS INC DYNE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $84.6M | 4,668,839 | — | 1.7% | — | |
| — | BCRXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOCRYST PHARMACEUTICALS INC BIOCRYST PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $70.8M | 7,434,033 | — | 1.4% | — | |
| — | ORKAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ORUKA THERAPEUTICS INC ORUKA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $68.4M | 1,395,501 | — | 1.3% | — | |
| — | AORTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ARTIVION INC ARTIVION INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $60.0M | 1,637,290 | — | 1.2% | — | |
| — | — | NURIX THERAPEUTICS INC NURIX THERAPEUTICS INC · COM CUSIP 67080M103 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $57.5M | 3,710,877 | — | 1.1% | — | |
| — | MRNAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MODERNA INC MODERNA INC · COM · PUT CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $50.8M | 1,000,000 | — | 1.0% | — | |
| — | — | NAUTILUS BIOTECHNOLOGY INC NAUTILUS BIOTECHNOLOGY INC · COM CUSIP 63909J108 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $48.9M | 12,594,211 | — | 1.0% | — | |
| — | — | CYTOMX THERAPEUTICS INC. CYTOMX THERAPEUTICS INC. · COM CUSIP 23284F105 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $47.5M | 10,098,824 | — | 0.9% | — | |
| — | — | ALTO NEUROSCIENCE INC ALTO NEUROSCIENCE INC · COM SHS CUSIP 02157Q109 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $45.2M | 2,009,893 | — | 0.9% | — | |
| — | — | ENGENE HOLDINGS INC ENGENE HOLDINGS INC · COM CUSIP 29286M105 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $39.7M | 5,827,506 | — | 0.8% | — | |
| — | — | IMMUNOVANT INC IMMUNOVANT INC · COM CUSIP 45258J102 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $39.7M | 1,597,383 | — | 0.8% | — | |
| — | ISRGverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INTUITIVE SURGICAL INC INTUITIVE SURGICAL INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $39.4M | 85,419 | — | 0.8% | — | |
| — | IONSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IONIS PHARMACEUTICALS INC IONIS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $37.8M | 504,000 | — | 0.7% | — | |
| — | — | DAY ONE BIOPHARMACEUTICALS I DAY ONE BIOPHARMACEUTICALS I · COM CUSIP 23954D109 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $37.6M | 1,755,799 | — | 0.7% | — | |
| — | ABVXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ABIVAX SA ABIVAX SA · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $36.6M | 328,884 | — | 0.7% | — | |
| — | — | CORVUS PHARMACEUTICALS INC CORVUS PHARMACEUTICALS INC · COM CUSIP 221015100 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $33.5M | 2,292,441 | — | 0.7% | — | |
| — | RGENverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REPLIGEN CORP REPLIGEN CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $33.1M | 280,541 | — | 0.6% | — | |
| — | JAZZverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | JAZZ PHARMACEUTICALS PLC JAZZ PHARMACEUTICALS PLC · SHS USD CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $32.1M | 170,000 | — | 0.6% | — | |
| — | DMRAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DAMORA THERAPEUTICS INC DAMORA THERAPEUTICS INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $31.7M | 1,223,000 | — | 0.6% | — | |
| — | — | X4 PHARMACEUTICALS INC X4 PHARMACEUTICALS INC · COM NEW CUSIP 98420X202 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $27.8M | 6,737,648 | — | 0.5% | — | |
| — | GHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GUARDANT HEALTH INC GUARDANT HEALTH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $27.7M | 300,000 | — | 0.5% | — | |
| — | — | BRIGHT MINDS BIOSCIENCES INC BRIGHT MINDS BIOSCIENCES INC · COM NEW CUSIP 10919W405 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $27.5M | 377,544 | — | 0.5% | — | |
| — | — | INVIVYD INC INVIVYD INC · COM CUSIP 00534A102 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $27.1M | 20,859,303 | — | 0.5% | — | |
| — | SIONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SIONNA THERAPEUTICS INC SIONNA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $26.4M | 658,439 | — | 0.5% | — | |
| — | RVMDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REVOLUTION MEDICINES INC | $25.6M | 508,600 | — | 0.5% | — | |
| — | AXSMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | AXSOME THERAPEUTICS INC. AXSOME THERAPEUTICS INC. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $25.3M | 149,950 | — | 0.5% | — | |
| — | — | SAB BIOTHERAPEUTICS INC SAB BIOTHERAPEUTICS INC · COM NEW CUSIP 78397T202 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $24.6M | 6,431,743 | — | 0.5% | — | |
| — | — | BELITE BIO INC BELITE BIO INC · SPONSORED ADS CUSIP 07782B104 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $24.2M | 151,979 | — | 0.5% | — | |
| — | — | TENAX THERAPEUTICS INC TENAX THERAPEUTICS INC · COM NEW CUSIP 88032L605 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $23.2M | 1,447,782 | — | 0.5% | — | |
| — | — | AXOGEN INC AXOGEN INC · COM CUSIP 05463X106 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $23.1M | 697,312 | — | 0.5% | — | |
| — | — | VIRIDIAN THERAPEUTICS INC VIRIDIAN THERAPEUTICS INC · COM CUSIP 92790C104 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $22.9M | 1,170,829 | — | 0.4% | — | |
| — | — | ORCHESTRA BIOMED HLDGS INC ORCHESTRA BIOMED HLDGS INC · COM CUSIP 68572M106 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $21.4M | 5,037,906 | — | 0.4% | — | |
| — | — | RAPPORT THERAPEUTICS INC RAPPORT THERAPEUTICS INC · COM CUSIP 75383L102 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $21.1M | 673,923 | — | 0.4% | — | |
| — | — | DBV TECHNOLOGIES S A DBV TECHNOLOGIES S A · SPONSORED ADS CUSIP 23306J309 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $20.1M | 964,391 | — | 0.4% | — | |
| — | — | LEONABIO INC LEONABIO INC · COM CUSIP 04746L203 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $19.1M | 1,859,322 | — | 0.4% | — | |
| — | — | ANTERIS TECHNOLOGIES GLOBAL ANTERIS TECHNOLOGIES GLOBAL · COM CUSIP 03675P102 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $19.0M | 3,425,476 | — | 0.4% | — | |
| — | — | SUTRO BIOPHARMA INC SUTRO BIOPHARMA INC · COM SHS CUSIP 869367201 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $17.8M | 715,307 | — | 0.3% | — | |
| — | TNGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TANGO THERAPEUTICS INC TANGO THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $16.9M | 808,153 | — | 0.3% | — | |
| — | — | CONTINEUM THERAPEUTICS INC CONTINEUM THERAPEUTICS INC · CL A CUSIP 21217B100 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $16.4M | 1,255,592 | — | 0.3% | — | |
| — | — | PALISADE BIO INC PALISADE BIO INC · COM CUSIP 696389402 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $15.6M | 8,928,149 | — | 0.3% | — | |
| — | — | OCULIS HOLDING AG OCULIS HOLDING AG · ORDINARY SHARES CUSIP H5870P102 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $13.1M | 493,827 | — | 0.3% | — | |
| — | IRTCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IRHYTHM HOLDINGS INC IRHYTHM HOLDINGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $12.4M | 105,026 | — | 0.2% | — | |
| — | — | ADAGIO MED HLDGS INC ADAGIO MED HLDGS INC · COM CUSIP 00534B100 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $11.0M | 9,876,576 | — | 0.2% | — | |
| — | — | EVOMMUNE INC EVOMMUNE INC · COM SHS CUSIP 30054Y107 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $10.3M | 448,350 | — | 0.2% | — | |
| — | — | PHATHOM PHARMACEUTICALS INC PHATHOM PHARMACEUTICALS INC · COM CUSIP 71722W107 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $10.3M | 925,000 | — | 0.2% | — | |
| — | — | NEUMORA THERAPEUTICS INC. NEUMORA THERAPEUTICS INC. · COM CUSIP 640979100 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $10.0M | 5,104,097 | — | 0.2% | — | |
| — | — | OMADA HEALTH INC OMADA HEALTH INC · COM CUSIP 68170A108 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $9.9M | 786,330 | — | 0.2% | — | |
| — | NBIXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NEUROCRINE BIOSCIENCES INC NEUROCRINE BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $8.6M | 65,050 | — | 0.2% | — | |
| — | — | BETA BIONICS INC BETA BIONICS INC · COM CUSIP 08659B102 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $8.4M | 842,944 | — | 0.2% | — | |
| — | — | OPUS GENETICS INC OPUS GENETICS INC · COM CUSIP 67577R102 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $8.4M | 1,835,842 | — | 0.2% | — | |
| — | BLLNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BILLIONTOONE INC BILLIONTOONE INC · CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $7.2M | 91,812 | — | 0.1% | — | |
| — | TWSTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TWIST BIOSCIENCE CORP TWIST BIOSCIENCE CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $7.1M | 150,000 | — | 0.1% | — | |
| — | — | SURROZEN INC | $6.7M | 396,059 | — | 0.1% | — | |
| — | — | AGOMAB THERAPEUTICS NV AGOMAB THERAPEUTICS NV · SPONSORED ADS CUSIP 00860C102 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $6.3M | 600,000 | — | 0.1% | — | |
| — | — | EVOLUS INC EVOLUS INC · COM CUSIP 30052C107 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $5.3M | 1,286,862 | — | 0.1% | — | |
| — | COGTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | COGENT BIOSCIENCES INC COGENT BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $4.7M | 121,082 | — | 0.1% | — | |
| — | — | OCULAR THERAPEUTIX INC OCULAR THERAPEUTIX INC · COM · CALL CUSIP 67576A100 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $4.2M | 500,000 | — | 0.1% | — | |
| — | ADMAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ADMA BIOLOGICS INC ADMA BIOLOGICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $4.2M | 467,233 | — | 0.1% | — | |
| — | — | INHIBIKASE THERAPEUTICS INC INHIBIKASE THERAPEUTICS INC · COM NEW CUSIP 45719W205 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $3.9M | 2,315,000 | — | 0.1% | — | |
| — | CBIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CRESCENT BIOPHARMA INC. CRESCENT BIOPHARMA INC. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $3.8M | 206,942 | — | 0.1% | — | |
| — | — | APELLIS PHARMACEUTICALS INC APELLIS PHARMACEUTICALS INC · COM CUSIP 03753U106 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $3.3M | 80,956 | — | 0.1% | — | |
| — | — | OUTSET MED INC OUTSET MED INC · COM NEW CUSIP 690145206 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $3.2M | 833,333 | — | 0.1% | — | |
| — | — | EDESA BIOTECH INC EDESA BIOTECH INC · COM NEW CUSIP 27966L306 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $2.9M | 563,239 | — | 0.1% | — | |
| — | ADPTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ADAPTIVE BIOTECHNOLOGIES COR ADAPTIVE BIOTECHNOLOGIES COR · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $2.1M | 152,500 | — | 0.0% | — | |
| — | — | AVALO THERAPEUTICS INC AVALO THERAPEUTICS INC · COM NEW CUSIP 05338F306 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $2.1M | 139,667 | — | 0.0% | — | |
| — | — | CONNECT BIOPHARMA HLDGS LTD CONNECT BIOPHARMA HLDGS LTD · SHS CUSIP G23549101 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $2.1M | 792,696 | — | 0.0% | — | |
| — | CORTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CORCEPT THERAPEUTICS INC CORCEPT THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $2.0M | 50,000 | — | 0.0% | — | |
| — | MDLNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MEDLINE INC MEDLINE INC · COM CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $1.2M | 28,000 | — | 0.0% | — | |
| — | — | PALATIN TECHNOLOGIES INC PALATIN TECHNOLOGIES INC · COM NEW CUSIP 696077601 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $1.1M | 61,945 | — | 0.0% | — | |
| — | — | CUMBERLAND PHARMACEUTICALS I CUMBERLAND PHARMACEUTICALS I · COM CUSIP 230770109 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $640K | 196,978 | — | 0.0% | — | |
| — | — | EXAGEN INC EXAGEN INC · COM CUSIP 30068X103 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $345K | 114,893 | — | 0.0% | — | |
| — | — | ENSYSCE BIOSCIENCES INC ENSYSCE BIOSCIENCES INC · COM NEW CUSIP 293602504 quarter ended 2026-03-31 filed filed 2026-05-29 +59d | $46.7K | 86,666 | — | 0.0% | — |
1–91 of 91 issuers · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).